Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Carboplatin in Triple Negative Breast Cancer: NCT06351332 Clinical Landscape Report 2026
16 October 2026
NCT06351332 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tamoxifen Citrate in Diffuse Large B-Cell Lymphoma: NCT06355401 Clinical Landscape Report 2026
16 October 2026
NCT06355401 clinical landscape for Diffuse Large B-Cell Lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Dasatinib in Triple Negative Breast Cancer: NCT06355037 Clinical Landscape Report 2026
16 October 2026
NCT06355037 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Inosine in Triple Negative Breast Cancer: NCT06355024 Clinical Landscape Report 2026
16 October 2026
NCT06355024 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
INBRX-106 in Triple Negative Breast Cancer: NCT06353997 Clinical Landscape Report 2026
16 October 2026
NCT06353997 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cisplatin/Vinblastine/SHAO in Triple Negative Breast Cancer: NCT06358573 Clinical Landscape Report 2026
16 October 2026
NCT06358573 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Tombestomig in Neoplasm Metastasis: PACTR202404480503746 Clinical Landscape Report 2026
16 October 2026
PACTR202404480503746 clinical landscape for Neoplasm Metastasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Sulfasalazine in Systemic Lupus Erythematosus: NCT06360068 Clinical Landscape Report 2026
16 October 2026
NCT06360068 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Abacavir Sulfate/Lamivudine in Systemic Lupus Erythematosus: NCT06356740 Clinical Landscape Report 2026
16 October 2026
NCT06356740 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Cyclophosphamide in Large B-cell lymphoma: NCT06356129 Clinical Landscape Report 2026
16 October 2026
NCT06356129 clinical landscape for Large B-cell lymphoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
ST-1898 in Unresectable Acral Lentiginous Melanoma: NCT06359860 Clinical Landscape Report 2026
16 October 2026
NCT06359860 clinical landscape for Unresectable Acral Lentiginous Melanoma: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
Tislelizumab in Advanced Endometrial Carcinoma: NCT06363708 Clinical Landscape Report 2026
16 October 2026
NCT06363708 clinical landscape for Advanced Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.